^99Tc^m—MIBI心肌灌注显像评价代谢综合征患者心肌血流

目的应用MPI评价代谢综合征（MS）患者心肌血流灌注情况。方法选择确诊或疑似冠心病患者342例行常规门控运动＋静息MPI;根据代谢指标异常情况分为4组,组1：无代谢指标异常;组2：具有1个代谢指标异常;组3：具有2个代谢指标异常;组4：具有3个或3个以上代谢指标异常。分析代谢指标异常数量与MPI的关系。对符合中华医学会糖尿病分会MS诊断标准、在显像前后1个月内行CAG检查的103例患者的MPI结果,以CAG结果为标准,分析2种方法间诊断的一致性。采用SPSS13．0软件,组间心肌灌注异常的发生率比较采用x。检验,方法间的一致性分析用Kappa检验。结果（1）与CAG比较,MPI诊断冠心病的灵敏度为80．5％（33／41）,特异性85．5％（53／62）,阳性预测值78．6％（33／42）,阴性预测值86．9％（53／61）,诊断准确性为83．5％（86／103）,惭值为0．657,P〈0．001。（2）随代谢指标异常数量增加,心肌灌注异常的发生率增加：组1为23．3％（10／43）,组2为32．9％（26／79）,组3为54．4％（56／103）,组4为57．3％（67／117）,X2：23．22,P〈0．001。结论MPI可以应用于IS患者的心肌血流评估;代谢指标异常数量增加,心肌灌注异常的发生率增加。     

盐酸去甲乌药碱负荷99Tcm-MIBI心肌灌注显像在冠心病诊断中的价值

目的 评估盐酸去甲乌药碱(HG)负荷MPI对冠心病的诊断价值.方法 62例疑诊冠心病患者行HG负荷-静息99Tcm-MIBI MPI和CAG.以CAG结果为“金标准”,计算HG负荷显像诊断冠心病的灵敏度、特异性准确性、阳性预测值和阴性预测值.结果 以冠状动脉(简称冠脉)主支或其一级分支狭窄≥50％作为诊断标准,62例患者中CAG阳性38例(61.3％),阴性24例(38.7％);阳性者中单支病变24例,双支病变9例,三支病变5例.CAG阳性者中HG负荷显像异常22例;阴性者中HG负荷显像正常者22例.HG负荷显像诊断冠心病的灵敏度为57.9％(22/38),特异性为91.7％(22/24),准确性为71.0％(44/62),阳性预测值为91.7％(22/24),阴性预测值为57.9％(22/38).62例患者显像时发生不良反应22例(35.5％),但均能在短时内缓解,完成检查.结论 盐酸去甲乌药碱负荷99Tcm-MIBI心肌显像对冠心病的诊断价值尚可,不良反应较少;该药有望成为MPI新型负荷药物.     

99 Tcm-MIBI SPECT心肌显像对冠状动脉介入治疗术后预后判断的价值

目的评估99Tcm-甲氧基异丁基异腈(MIBI)运动-静息SPECT心肌显像对冠状动脉介入治疗 (PCI) 后患者长期预后判断的价值.方法对接受PCI并于1992年1月～2001年12月行99Tcm-MIBI运动-静息心肌灌注显像的冠心病患者进行回顾性随访.图像分析采用20节段,4分打分法,获得运动总积分(SSS)、静息总积分(SRS)和心肌缺血分(SDS).结果根据心肌显像结果将患者分为正常组(SSS=0,153例)、固定缺损组 (SDS<3,SRS>1,100例) 和可逆性缺损组(SDS≥3,65例).急性心肌梗死(AMI)和死亡为恶性心脏事件,再次血运重建术(心肌显像后≥3个月)为良性心脏事件.318例入选患者,随访时间(38±27)个月.随访期间,51例(16.0%)患者发生心脏事件,其中1例死亡,13例AMI,9例冠状动脉搭桥术,28例2次PCI.可逆性缺损组的年恶性心脏事件发生率为3.9%,与正常组(0.2%)相比差异有显著性(χ2=7.71,P=0.005).可逆性缺损组的年良性心脏事件发生率为10.7%,与固定缺损组 (2.5%,χ2=17.69, P<0.000 1)和正常组(1.5%,χ2=33.89,P<0.000 1)相比差异均有显著性.心肌显像正常或为可逆性缺损则恶性和良性心脏事件发生率在有心绞痛和无心绞痛患者间差异无显著性(P>0.05).而心肌显像为固定性缺损区,则有心绞痛症状的良性心脏事件发生率明显高于无心绞痛者(15.9%和1.8%,χ2=6.11,P=0.013).Cox多元线性回归分析示SSS(χ2=12.70,P<0.000 1)和SDS(χ2=5.80,P<0.05)为预测恶性心脏事件的独立危险因子;而SDS(χ2=11.72,P<0.000 1)为预测良性心脏事件的独立危险因子.结论 PCI后患者,如99Tcm-MIBI心肌SPECT显像正常,则预后良好;如心肌显像呈可逆性缺损,心脏事件发生率明显增加,心脏事件的发生与有无心绞痛无明显关系;如心肌显像为固定性缺损,则有心绞痛症状患者接受再次血运重建术的可能性明显高于无心绞痛症状患者.因此,该方法对于PCI后患者的预后估测和进一步治疗方案的制定有较为重要的临床价值.     

99 Tcm-tetrofosmin与99Tcm-MIBI心肌显像的对比研究

目的　评价99Tcm 1,2 双 [双 2 乙氧乙基膦 ]乙烷 (tetrofosmin)诊断冠心病的临床价值。方法　经冠脉造影、病历资料完整的 5 3例患者 ,其中行99Tcm tetrofosmin心肌灌注显像 2 7例 ,行99Tcm MIBI心肌灌注显像 2 6例。运动负荷试验按Bruce方案进行。Tetrofosmin显像于给药后 30min行心肌断层显像 ,间隔 2 4h后作静息心肌断层显像 ,运动 静息一日法则在 4h后作静息心肌断层显像 ;MIBI显像于给药后 1～ 2h行心肌断层显像 ,48h后作静息心肌断层显像。冠脉造影采用Judkins法。结果　99Tcm tetrofosmin心肌灌注显像 ,运动、静息显像以及运动 静息一日法心肌显像均获得了清晰的心肌断层图像 ,均未发现邻近器官有明显的放射性干扰。Tetrofosmin诊断冠心病的灵敏度为 90 % ,MIBI的诊断灵敏度为 94% ,两者间差异无显著性 (P >0 .0 5 )。Tetrofosmin的检测效率为 85 .2 % ,MIBI的检测效率为88.5 % ,两者间差异无显著性 (P >0 .0 5 )。Tetrofosmin和MIBI的阳性预测值分别为 90 .0 %和 89.5 % ,诊断特异性分别为 71%和 75 %。结论　99Tcm tetrofosmin心肌显像对冠心病心肌缺血具有较高的诊断价值 ,且适用于运动 静息一日法心肌显像     

99Tcm-MIBI运动负荷-静息心肌灌注显像对冠心病患者经皮腔内冠状动脉血管成形术的疗效评价

Objective To evaluate the outcomes of stress-rest 99Tcm-MIBI peffusion imaging in patients with percutaneous transluminal coronary angioplasty (PTCA). Methods Twenty patients with coronary heart disease underwent repeated 99Tcm-MIBI stress-rest perfusion imaging before and after PICA, and semi-quantitative analysis, 8 cases of them repeated coronary angiography after 6 monthes. Results Twenty patients with total of 27 coronary artery stenosis were distended, the average vascular stenosis were (84.3±9.2)% before PTCA, and were reduced to(31.2±9.1)% after PTCA. Stress-rest perfusion imaging showed myocardial segments were reversible defect (myocardial ischemia) from 55 (30.6%) befor PTCA to 10 (5.6%) after PTCA, there were significant difference (X2=38.02, P<0.005). The improved rate was 81.8%, 8 patients underwent repeated stress-rest SPECT imaging after 6 monthes, 3 cases appears ischemia segment, and coronary angiography confirmed was restenosis. Conclusion 99Tcm-MIBI stress-rest perfusion imaging is a useful noninvasive method for evaluating the effect of PTCA and for restenosis.     

99Tcm-MIBI运动负荷-静息心肌灌注显像对冠心病患者经皮腔内冠状动脉血管成形术的疗效评价

Objective To evaluate the outcomes of stress-rest 99Tcm-MIBI peffusion imaging in patients with percutaneous transluminal coronary angioplasty (PTCA). Methods Twenty patients with coronary heart disease underwent repeated 99Tcm-MIBI stress-rest perfusion imaging before and after PICA, and semi-quantitative analysis, 8 cases of them repeated coronary angiography after 6 monthes. Results Twenty patients with total of 27 coronary artery stenosis were distended, the average vascular stenosis were (84.3±9.2)% before PTCA, and were reduced to(31.2±9.1)% after PTCA. Stress-rest perfusion imaging showed myocardial segments were reversible defect (myocardial ischemia) from 55 (30.6%) befor PTCA to 10 (5.6%) after PTCA, there were significant difference (X2=38.02, P<0.005). The improved rate was 81.8%, 8 patients underwent repeated stress-rest SPECT imaging after 6 monthes, 3 cases appears ischemia segment, and coronary angiography confirmed was restenosis. Conclusion 99Tcm-MIBI stress-rest perfusion imaging is a useful noninvasive method for evaluating the effect of PTCA and for restenosis.     

99Tcm-MIBI运动负荷-静息心肌灌注显像对冠心病患者经皮腔内冠状动脉血管成形术的疗效评价

Objective To evaluate the outcomes of stress-rest 99Tcm-MIBI peffusion imaging in patients with percutaneous transluminal coronary angioplasty (PTCA). Methods Twenty patients with coronary heart disease underwent repeated 99Tcm-MIBI stress-rest perfusion imaging before and after PICA, and semi-quantitative analysis, 8 cases of them repeated coronary angiography after 6 monthes. Results Twenty patients with total of 27 coronary artery stenosis were distended, the average vascular stenosis were (84.3±9.2)% before PTCA, and were reduced to(31.2±9.1)% after PTCA. Stress-rest perfusion imaging showed myocardial segments were reversible defect (myocardial ischemia) from 55 (30.6%) befor PTCA to 10 (5.6%) after PTCA, there were significant difference (X2=38.02, P<0.005). The improved rate was 81.8%, 8 patients underwent repeated stress-rest SPECT imaging after 6 monthes, 3 cases appears ischemia segment, and coronary angiography confirmed was restenosis. Conclusion 99Tcm-MIBI stress-rest perfusion imaging is a useful noninvasive method for evaluating the effect of PTCA and for restenosis.     

99Tcm-MIBI运动负荷-静息心肌灌注显像对冠心病患者经皮腔内冠状动脉血管成形术的疗效评价

Objective To evaluate the outcomes of stress-rest 99Tcm-MIBI peffusion imaging in patients with percutaneous transluminal coronary angioplasty (PTCA). Methods Twenty patients with coronary heart disease underwent repeated 99Tcm-MIBI stress-rest perfusion imaging before and after PICA, and semi-quantitative analysis, 8 cases of them repeated coronary angiography after 6 monthes. Results Twenty patients with total of 27 coronary artery stenosis were distended, the average vascular stenosis were (84.3±9.2)% before PTCA, and were reduced to(31.2±9.1)% after PTCA. Stress-rest perfusion imaging showed myocardial segments were reversible defect (myocardial ischemia) from 55 (30.6%) befor PTCA to 10 (5.6%) after PTCA, there were significant difference (X2=38.02, P<0.005). The improved rate was 81.8%, 8 patients underwent repeated stress-rest SPECT imaging after 6 monthes, 3 cases appears ischemia segment, and coronary angiography confirmed was restenosis. Conclusion 99Tcm-MIBI stress-rest perfusion imaging is a useful noninvasive method for evaluating the effect of PTCA and for restenosis.     

99Tcm-MIBI运动负荷-静息心肌灌注显像对冠心病患者经皮腔内冠状动脉血管成形术的疗效评价

Objective To evaluate the outcomes of stress-rest 99Tcm-MIBI peffusion imaging in patients with percutaneous transluminal coronary angioplasty (PTCA). Methods Twenty patients with coronary heart disease underwent repeated 99Tcm-MIBI stress-rest perfusion imaging before and after PICA, and semi-quantitative analysis, 8 cases of them repeated coronary angiography after 6 monthes. Results Twenty patients with total of 27 coronary artery stenosis were distended, the average vascular stenosis were (84.3±9.2)% before PTCA, and were reduced to(31.2±9.1)% after PTCA. Stress-rest perfusion imaging showed myocardial segments were reversible defect (myocardial ischemia) from 55 (30.6%) befor PTCA to 10 (5.6%) after PTCA, there were significant difference (X2=38.02, P<0.005). The improved rate was 81.8%, 8 patients underwent repeated stress-rest SPECT imaging after 6 monthes, 3 cases appears ischemia segment, and coronary angiography confirmed was restenosis. Conclusion 99Tcm-MIBI stress-rest perfusion imaging is a useful noninvasive method for evaluating the effect of PTCA and for restenosis.     

99Tcm-MIBI运动负荷-静息心肌灌注显像对冠心病患者经皮腔内冠状动脉血管成形术的疗效评价

Objective To evaluate the outcomes of stress-rest 99Tcm-MIBI peffusion imaging in patients with percutaneous transluminal coronary angioplasty (PTCA). Methods Twenty patients with coronary heart disease underwent repeated 99Tcm-MIBI stress-rest perfusion imaging before and after PICA, and semi-quantitative analysis, 8 cases of them repeated coronary angiography after 6 monthes. Results Twenty patients with total of 27 coronary artery stenosis were distended, the average vascular stenosis were (84.3±9.2)% before PTCA, and were reduced to(31.2±9.1)% after PTCA. Stress-rest perfusion imaging showed myocardial segments were reversible defect (myocardial ischemia) from 55 (30.6%) befor PTCA to 10 (5.6%) after PTCA, there were significant difference (X2=38.02, P<0.005). The improved rate was 81.8%, 8 patients underwent repeated stress-rest SPECT imaging after 6 monthes, 3 cases appears ischemia segment, and coronary angiography confirmed was restenosis. Conclusion 99Tcm-MIBI stress-rest perfusion imaging is a useful noninvasive method for evaluating the effect of PTCA and for restenosis.     

腺苷负荷99Tcm—MIBI心肌显像在冠状动脉造影慢血流患者中的应用

目的探讨腺苷负荷99Tcm-甲氧基异丁基异腈（MIBI）心肌显像与冠状动脉（简称冠脉）造影慢血流现象的关系。方法44例患者均经冠脉造影及腺苷负荷99TcmMIBI心肌血流灌注显像,分析比较冠脉造影阳性组（P—CAG）12例,冠脉慢血流组（CSF）22例以及冠脉正常血流组（NCF）10例患者临床资料、腺苷心肌负荷显像改变、冠脉造影结果与腺苷负荷心肌显像的关系。结果采用方差分析、t检验或X^2检验比较。结果3组临床资料（包括年龄、性别和危险因素：高血压史、高脂血症及糖尿病发病率）差异均无统计学意义（年龄：t=0．27,0．54和0．59;性别：矿：0．92;危险因素：X^2=1．23;P均〉0．05）;CSF组冠脉心肌梗死溶栓疗法（TIMI）血流帧数明显多于NCF组（33．7±5．5和17．6±3．9,t=-9．58,P〈0．001）。P—CAG组12例,腺苷负荷心肌显像阳性率100％（12／12）;CSF组22例,阳性率77．3％（17／22）;NCF组10例,2例阳性。半定量靶心图分析示腺苷负荷试验心肌缺血范围（人均缺血节段数）CSF组多于NCF组（1．06±0．77和0．91±0．80,t=-2．02,P〈0．05）,少于P—CAG组（2．41±0．79,t=4．54,P〈0．001）。靶心图记分心肌缺血程度显示CSF组大于NCF组（8．01±6．06和2．73±2．60,t=-2．07,P〈0．05）,小于P—CAG组,但差异无统计学意义（14．07±12．77,t=1．44,P〉0．05）。结论腺苷负荷心肌灌注阳性显像中部分患者伴有冠脉造影慢血流现象,这为有明显胸痛症状但冠脉造影阴性的患者提供了诊断和治疗依据。     

阿托品-4 min腺苷负荷心肌灌注显像对冠心病的临床诊断价值

目的 评价阿托品-4 min腺苷负荷试验心肌灌注显像对冠心病的临床诊断价值.方法 将研究对象按性别、年龄、冠心病的严重程度[依据冠状动脉(简称冠脉)造影结果]及合并症等进行配对,分为阿托品-4 min腺苷负荷组(研究组)和6 min腺苷负荷组(对照组),每组28例.研究组在注射腺苷前10 min静脉注射阿托品0.5 mg.2组病例分别经肘静脉用注射泵持续注入腺苷,剂量为按体质量0.14 mg·kg-1·min-1,用药时间为4和6 min,于注射腺苷3 min末,分别从肘静脉注入99Tcm-甲氧基异丁基异腈(MIBI)740 MBq.腺苷负荷心肌灌注显像在注射显像剂后1.5 h进行,隔日进行静息心肌灌注显像.结果 (1)研究组和对照组腺苷负荷心肌显像诊断冠心病心肌缺血的灵敏度、特异性、准确性分别为85%,6/8,82%和86%,5/7,82%,2组比较χ2均＜0.001,P均＞0.05.(2)研究组腺苷负荷试验诊断单支、双支、三支冠脉狭窄病变的灵敏度分别为6/7,8/9和3/4,对照组分别为7/8,7/8和4/5,组间比较χ2均＜0.001,P＞0.05.(3)研究组和对照组不良反应总的发生率分别为82%和89%;2组各不良反应发生率除胸闷(43%和68%)差异有统计学意义(χ2=4.000,P＜0.05)以外,其余表现2组比较差异均无统计学意义.结论 阿托品-4 min腺苷负荷心肌灌注显像对冠心病心肌缺血有较高的诊断价值,可达到6 min腺苷负荷试验的诊断效能,且胸闷发生率低,更安全简便.     

运动负荷后早期门控心肌显像对冠心病严重三支病变的诊断价值

目的比较运动负荷早期(15～20min)^99Tc^m-甲氧基异丁基异腈(MIBI)门控心肌显像(G-MPI)和非门控心肌显像(NG-MPI)诊断冠心病(CAD)严重三支病变(狭窄≥70％)的价值。方法以冠状动脉(简称冠脉)造影(CAG)所示冠脉直径狭窄≥70％为严重CAD诊断标准，将同期做运动负荷^99Tc^m-MIBI SPECT G-MPI和CAG的215例患者分为CAD三支病变组(A组)与CAD非三支病变组(B组)。结果G-MPI与NG-MPI诊断严重CAD的灵敏度分别为95．3％(143／150例)和90．7％(136／150例，X^2=2．509，P=0．113)，特异性分别为80．0％(52／65例)和72．3％(47／65例，X^2=1．059，P=0．303)；诊断CAD三支病变的灵敏度分别为100％(51／51例)和92．2％(47／51例)，前者更好，且两者差异有显著性(X^2=4．163，P=0．041)。结论在诊断临床高危CAD严重三支病变时，G-MPI比NGMPI更有价值。     

CT血管成像检出心肌桥患者的^99Tc^m—MIBI门控心肌显像研究

目的探讨^99Tc^m-MIBI G-MPI对冠状动脉CT血管成像（CTA）检出心肌桥（MB）患者的临床价值。方法对象为62例（MB患者45例,对照组17例）经CTA（64排CT）检查并接受^99Tc^m-MIBIG-MPI的患者,分析其心肌灌注、室壁运动和左心室功能。所有患者行静息显像,其中17例MB患者和9例对照行运动负荷G-MPI。组间率的比较用,检验或确切概率法,计量资料用t检验比较差异。结果运动负荷和静息心肌显像对MB患者的心肌缺血和（或）灌注异常的阳性检出率分别为（1）门控半定量法：64．7％（11／17）、42．2％（19／45）;（2）目测法：41．2％（7／17）、22．2％（10／45）,静息门控半定量法和目测法的阳性检出率差异有统计学意义（P=0．035）。静息显像对不同位置[近段0／7、中段19．4％（6／31）、远段4／7]和深度[表浅型16．7％（7／42）、纵深型3／3]MB的心肌灌注异常阳性检出率差异有统计学意义（x2=7．086,P〈0．05;P=0．008）。门控半定量法评价17例（有负荷显像结果）MB中可逆性缺血、固定缺血和混合性缺血分别占35．3％、23．5％和5．9％;室壁运动和室壁增厚率类型总积分反向分布异常、可逆性异常、固定异常所占百分比分别是23．5％、23．5％、11．8％和35．3％、29．4％、5．9％。不论静息相还是运动负荷相,MB组和对照组间LVEF和高峰充盈率差异均无统计学意义（t=-0．564～1．292,P均〉0．05）。结论^99Tc^m -MIBIG—MPI对CTA检出的MB患者的心肌缺血和（或）灌注异常及左心室功能状况评价有一定价值。     

心肌灌注显像腺苷负荷试验致心电图改变分析

目的 评价腺苷负荷心肌灌注显像中患者的心电图变化.方法 回顾性分析2008年5月至12月完成腺苷负荷心肌灌注显像的641例患者腺苷药物负荷试验心电图变化和心肌灌注显像结果.统计学分析采用SAS 8.0软件,单因素分析采用t检验和χ2检验,多因素分析采用Logistic 回归分析.结果 腺苷注射前,641例患者中心电图正常436例（68.0%）,心电图异常205例（32.0%）.腺苷注射过程中新出现心律失常132例（20.6%,132/641）,其中房性早搏39例（29.5%）,室性早搏45例（34.1%）,窦房阻滞8例（6.1%）,一度房室传导阻滞7例（5.3%）,二度Ⅰ型房室传导阻滞26例（19.7%）,二度Ⅱ型房室传导阻滞6例（4.5%）,三度房室传导阻滞1例（0.8%）;需停药13例（9.8%）.腺苷注射终止后新出现心律失常28例（4.4%,28/641）,其中房性早搏16例（57.1%）,室性早搏11例（39.3%）,窦房阻滞1例（3.6%）.641例患者腺负荷试验中共35例（5.5%）出现心电图ST段压低＞0.1 mV,39例（6.1%）予停药处理,无一例急性心肌梗死及猝死;心肌灌注显像结果：36例心肌缺血改变,8例心肌梗死改变.Logistic回归分析示,用腺苷药前、中、后心律失常并不增加出现心肌缺血及心肌梗死改变的风险[P=0.9613,比值比（OR）=0.982,95%可信区间（CI）0.471～2.046;P=0.9511,OR＜0.001,95%CI：＜0.001,＞999.999;P=0.9931,OR＜0.001,95%CI：＜0.001,＞999.999],并且腺苷注射过程中出现与未出现房室传导阻滞患者的阳性心肌灌注显像结果及ST段压低的发生率差异均无统计学意义（χ2=2.5298,0.5317,P均＞0.05）.ST段压低＞0.1 mV的患者出现阳性心肌灌注显像结果的风险增加（P=0.0005,OR=5.608,95%CI2.110～14.905）.结论 腺苷负荷试验过程中心电图异常发生率较高,但多为一过性,出现心律失常并不意味着有心肌缺血.     

18F-FDG／99Tcm—MIBI双核素心肌断层显像检测急性心肌梗死患者存活心肌

目的探讨18F-FDG／99Tcm-MIBI双核素心肌断层显像检测AMI患者存活心肌,评价该方法对心功能改善及预后判断的价值。方法98例[男87例,女11例,年龄（58±11）岁]确诊为AMI患者,均行18F-FDG／99Tcm-MIBI双核素心肌断层显像,采用半定量方法将心肌分成9个节段,并评分,放射性轻度减低=1分,明显减低=2分,缺损=3分。根据灌注和代谢显像情况,两者不匹配视为存活心肌,两者匹配为心肌无存活。治疗前后行超声心动图检查观察LVEF变化;所有患者进行随访,统计心脏事件发生率,比较再血管化治疗和药物治疗患者的心脏事件发生率差别。频数的比较采用x2检验。结果心肌存活组患者27例,接受冠状动脉再血管化和药物治疗者分别为27和10例;心肌无存活组61例,接受冠状动脉再血管化治疗和药物治疗者分别为35和26例。无论是心肌存活组还是心肌无存活组,再血管化治疗和药物治疗相比较,心功能明显改善（LVEF提高≥10％）的患者比例差异均无统计学意义（心肌存活组：矿=0．509,P〉0．05;心肌无存活组：x2=0．035,P〉0．05）。平均随访时间为（234-11）个月,心肌存活组接受药物治疗患者的心脏事件发生率明显高于接受再血管化治疗的患者（50．0％和14．8％,X2=4．91,P〈0．05）;在心肌无存活组,药物治疗患者的心脏事件发生率也同样明显高于再血管化治疗（30．7％和5．7％,x2=6．83,P〈0．05）。结论利用18F-FDG／99Tcm-MIBI双核素心肌断层显像检测AMI患者存活心肌,以判断心功能改善和预后,具有一定价值,同时也有局限性,还需要大规模前瞻性研究进一步证实。     

99Tcm-MIBI心肌显像检测“罪犯”血管

目的 探讨^99Tc^m-甲氧基异丁基异腈（MIBI）心肌显像在检测“罪犯”血管中的价值。方法 选择冠状动脉造影证实有多支血管病变并成功进行经皮冠状动脉腔内成形术（PTCA）等血流重建治疗的冠心病患者46例，PTCA术前进行运动、静息、静脉滴注硝酸甘油介入^99Tc^m-MIBI心肌显像，明确缺血与存活心肌量最多的部位，以对应支配该部位的病变血管确定为“罪犯”血管。以术后疗效为标准，验证其准确性。结果 46例中，冠状动脉造影发现病变血管107支，心肌显像确定“罪犯”血管46支。临床对确定的“罪犯”血管进行相应的血流重建治疗，随访均有良好疗效。结论 运动、静息、静脉滴注硝酸甘油介入^99Tc^m-MIBI心肌显像检测“罪犯”血管准确可靠，实用可行。     

国产腺苷介入心肌灌注断层显像对心肌缺血的诊断价值

目的评价国产腺苷负荷心肌灌注断层显像对心肌缺血的诊断价值及腺苷试验的安全性。方法 102例临床疑冠心病患者行腺苷负荷/静息~(99)Tc~m-甲氧基异丁基异腈(MIBI)心肌灌注断层显像,其中70例显像1周内又行冠状动脉(简称冠脉)造影检查。腺苷按体重0.84 mg·kg~(-1)通过输液泵静脉双通路给药,对心肌灌注断层显像图作定性分析。结果 70例行冠脉造影者中正常31例,有冠脉狭窄病变者39例(单支病变19例,双支病变10例,3支病变10例);共检出病变血管69支,累及左前降支32支,左回旋支16支,右冠脉20支,左主干1支。腺苷负荷心肌灌注断层显像正常33例,心肌缺血37例,其对冠心病心肌缺血诊断的灵敏度为82.05%(32/39例),特异性为83.87%(26/31例),准确性为82.86%(58/70例),阳性预测值为86.49%(32/37例),阴性预测值为78.79%(26/33例)。对各病变血管检出的灵敏度为:左前降支75.00%(24/32支),左回旋支62.50%(10/16支),右冠脉80.00%(16/20支)。对单支、双支、3支血管病变诊断的灵敏度分别为68 42%、90.00%和100%。腺苷负荷心肌灌注断层显像对病变冠脉诊断总灵敏度为73.53%(50/68支),特异性96.48%(137/142支),准确性89.05%(187/210支),阳性预测值90.91%(50/55支),阴性预测值88.39%(137/155支)。腺苷试验不良反应轻,时间短,发生率为85.29%(87/102例)。结论国产腺苷负荷试验介入~(99)Tc~m-MIBI 心肌灌注断层显像安全可靠。